Skip to main content

Table 2 Ezetimibe plus rosuvastatin versus rosuvastatin monotherapy: longitudinal changes in liver fat and liver fibrosis

From: Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)

  

Ezetimibe + rosuvastatin (n = 31)

 

Rosuvastatin alone (n = 33)

Difference between groups

Liver segment

Baseline

Post-treatment

p-value

Baseline

Post-treatment

p-value

p-value

I

16.6 (8.2)

11.3 (6.4)

< 0.001

13.2 (7.3)

11.5 (7.0)

0.042

0.012

II

16.7 (8.4)

10.8 (6.0)

< 0.001

14.2 (7.4)

11.8 (7.4)

0.006

0.012

III

17.1 (8.3)

11.2 (6.6)

< 0.001

14.2 (7.6)

11.9 (7.2)

0.012

0.011

IV (A)

18.0 (8.4)

12.4 (6.7)

< 0.001

15.3 (7.9)

12.5 (7.5)

0.004

0.038

IV (B)

18.9 (8.8)

13.4 (7.5)

< 0.001

15.9 (7.3)

13.2 (7.8)

0.003

0.051

V

18.9 (8.7)

12.9 (6.7)

< 0.001

16.1 (7.6)

13.2 (7.8)

0.002

0.029

VI

18.1 (8.3)

12.4 (6.7)

< 0.001

14.5 (7.5)

11.7 (7.6)

0.001

0.039

VII

18.6 (7.9)

12.5 (6.5)

< 0.001

15.2 (7.2)

12.4 (7.3)

0.001

0.018

VIII

19.6 (8.5)

13.5 (7.2)

< 0.001

16.6 (7.4)

13.6 (7.9)

0.002

0.028

MRI-PDFF average, %

18.1 (8.2)

12.3 (6.4)

< 0.001

15.0 (7.3)

12.4 (7.4)

0.003

0.020

MRE, kPa

2.0 (0.5)

2.1 (0.5)

0.507

2.2 (0.4)

2.2 (0.7)

0.539

0.898

  1. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) with colocalized MRI measurements was used in the longitudinal liver fat mapping. Longitudinal changes in liver fibrosis were measured using magnetic resonance elastography (MRE). Data are expressed as mean (SD) or difference with p-values from paired t-test or per-protocol analysis
  2. Abbreviations: MRI-PDFF magnetic resonance imaging proton density fat fraction, MRE magnetic resonance elastography